Biguanides Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Biguanides represent one of the oldest and most widely prescribed classes of oral antidiabetic drugs, with Metformin serving as the first-line pharmacological treatment for type 2 diabetes per most major clinical guidelines. The global market includes immediate-release and extended-release formulations, with Metformin accounting for the dominant share of total market value and volume. Several research firms project the market expanding from approximately $4.6 billion in 2025 to between $5.81 billion and $5.98 billion by 2029.

• •Primary molecules: Metformin (dominant), Phenformin (largely withdrawn in many markets), and Buformin (limited availability)
• •Market valued at ~$4.6 billion in 2025 with a projected CAGR of approximately 5.9% through 2029
• •Oral antidiabetic drug class with established efficacy and safety profile backed by decades of clinical use

The escalating global prevalence of type 2 diabetes is the primary engine of market expansion, with the International Diabetes Federation estimating hundreds of millions of adults living with the condition worldwide. Generic availability and low manufacturing costs have made Metformin one of the most affordable first-line therapies, driving penetration in both developed and developing healthcare markets. National treatment guidelines across most major markets continue to designate biguanides as preferred first-line therapy, sustaining stable demand.

• •Rising global diabetes incidence driven by aging populations, sedentary lifestyles, and increasing obesity rates
• •Patent expirations have enabled widespread generic Metformin production, dramatically improving affordability and access in emerging markets
• •Clinical guidelines from bodies including the American Diabetes Association and WHO consistently recommend Metformin as first-line therapy for type 2 diabetes

The market is categorized by molecule type, with Metformin commanding the overwhelming majority of revenue, followed by residual demand for Phenformin and Buformin in select markets where they remain approved. Geographically, North America and Europe constitute the largest regional markets, supported by high diabetes prevalence and established healthcare infrastructure. Asia-Pacific is the fastest-growing region, fueled by rising diabetes rates in China and India, expanding healthcare access, and increasing local manufacturing capacity.

• •By molecule: Metformin (over 95% share), Phenformin (limited, largely discontinued), and Buformin (niche markets)
• •By region: North America leads in revenue, followed by Europe; Asia-Pacific is the highest-growth regional market
• •By formulation: immediate-release tablets remain dominant, though extended-release formulations are gaining market share

What are the recent trends and outlook?

Extended-release Metformin formulations continue to gain preference over immediate-release versions due to improved gastrointestinal tolerability and once-daily dosing convenience. Fixed-dose combination therapies pairing Metformin with DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists represent a growing segment of the broader antidiabetic market. Ongoing research into Metformin's potential applications beyond diabetes, including oncology, cardiovascular disease, and aging research, could open new market opportunities in the longer term.

• •Extended-release formulations and fixed-dose combination therapies are growing faster than conventional immediate-release tablets
• •Emerging scientific research exploring Metformin's pleiotropic effects in non-diabetic conditions may broaden the drug's addressable market
• •Market consolidation among generic manufacturers and increasing regulatory scrutiny of manufacturing standards are shaping the competitive environment